Mechanisms of Eosinophilia in the Pathogenesis of Hypereosinophilic Disorders

Immunology and Allergy Clinics of North America

Volumn 27, Issue 3, 2007, Pages 357-375

  Ackerman, Steven J ^a   Bochner, Bruce S ^b  

^a UNIVERSITY OF ILLINOIS   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; INTERLEUKIN 5; MEPOLIZUMAB;

CELL ACTIVATION; CELL DIFFERENTIATION; CELL LINEAGE; CELL MIGRATION; CELL SURVIVAL; DEGRANULATION; EOSINOPHILIA; HUMAN; HYPEREOSINOPHILIC SYNDROME; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; TRANSCRIPTION REGULATION;

ANIMALS; CELL DEGRANULATION; CHEMOTACTIC FACTORS, EOSINOPHIL; CYTOKINES; EOSINOPHIL GRANULE PROTEINS; EOSINOPHILS; HUMANS; HYPEREOSINOPHILIC SYNDROME; INFLAMMATION MEDIATORS; LEUKOPOIESIS;

EID: 34548537191     PISSN: 08898561     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.iac.2007.07.004     Document Type: Review

References (154)

1. Kay A.B. The role of eosinophils in the pathogenesis of asthma. Trends Mol Med 11 4 (2005) 148-152
2. Kay A.B., Phipps S., and Robinson D.S. A role for eosinophils in airway remodelling in asthma. Trends Immunol 25 9 (2004) 477-482
3. Gomes I., Mathur S.K., Espenshade B.M., et al. Eosinophil-fibroblast interactions induce fibroblast IL-6 secretion and extracellular matrix gene expression: implications in fibrogenesis. J Allergy Clin Immunol 116 4 (2005) 796-804
4. Lee J.J., Dimina D., Macias M.P., et al. Defining a link with asthma in mice congenitally deficient in eosinophils. Science 305 5691 (2004) 1773-1776
5. Humbles A.A., Lloyd C.M., McMillan S.J., et al. A critical role for eosinophils in allergic airways remodeling. Science 305 5691 (2004) 1776-1779
6. Phipps S., Flood-Page P., Menzies-Gow A., et al. Intravenous anti-IL-5 monoclonal antibody reduces eosinophils and tenascin deposition in allergen-challenged human atopic skin. J Invest Dermatol 122 6 (2004) 1406-1412
7. Flood-Page P., Menzies-Gow A., Phipps S., et al. Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. J Clin Invest 112 7 (2003) 1029-1036
8. Stein M.L., Collins M.H., Villanueva J.M., et al. Anti-IL-5 (Mepolizumab) therapy for eosinophilic esophagitis. J Allergy Clin Immunol 118 6 (2006) 1312-1319
9. Rothenberg M.E., Gleich G.J., Roufosse F.E., et al. Steroid-sparing effects of anti-IL-5 monoclonal antibody (Mepolizumab) therapy in patients with HES: a multicenter, randomized, double-blind, placebo-controlled trial. Blood [ASH Annual Meeting Abstracts] 108 (2006) 373
10. Takatsu K., Tominaga A., Harada N., et al. T cell-replacing factor (TRF)/interleukin 5 (IL-5): molecular and functional properties. Immunol Rev 102 (1988) 107-135
11. Plaut M., Pierce J.H., Watson C.J., et al. Mast cell lines produce lymphokines in response to cross-linkage of Fc epsilon RI or to calcium ionophores. Nature 339 6219 (1989) 64-67
12. Galli S.J., Gordon J.R., Wershil B.K., et al. Mast cell and eosinophil cytokines in allergy and inflammation. In: Kay A.B., and Gleich G.J. (Eds). Eosinophils in allergy and inflammation vol. 2 (1994), Marcel Dekker, New York 255-280
13. Palacios R., Karasuyama H., and Rolink A. Ly1+ PRO-B lymphocyte clones. Phenotype, growth requirements and differentiation in vitro and in vivo. EMBO J 6 12 (1987) 3687-3693
14. Takatsu K., Yamaguchi N., Hitoshi Y., et al. Signal transduction through interleukin-5 receptors. Cold Spring Harb Symp Quant Biol 2 (1989) 745-751
15. Yamaguchi Y., Suda T., Suda J., et al. Purified interleukin 5 supports the terminal differentiation and proliferation of murine eosinophilic precursors. J Exp Med 167 1 (1988) 43-56
16. Sanderson C.J. Eosinophil differentiation factor (interleukin-5). Immunol Ser 49 (1990) 231-256
17. Sanderson C.J. Control of eosinophilia. Int Arch Allergy Appl Immunol 94 1-4 (1991) 122-126
18. Owen W.F., Rothenberg M.E., Petersen J., et al. Interleukin 5 and phenotypically altered eosinophils in the blood of patients with the idiopathic hypereosinophilic syndrome. J Exp Med 170 1 (1989) 343-348
19. Owen Jr. W., Petersen J., Sheff D.M., et al. Hypodense eosinophils and interleukin 5 activity in the blood of patients with the eosinophilia-myalgia syndrome. Proc Natl Acad Sci U S A 87 21 (1990) 8647-8651
20. Sanderson C.J. Interleukin-5, eosinophils, and disease. Blood 79 12 (1992) 3101-3109
21. Dent L.A., Strath M., Mellor A.L., et al. Eosinophilia in transgenic mice expressing Interleukin-5. J Exp Med 172 5 (1990) 1425-1431
22. Tominaga A., Takaki S., Koyama N., et al. Transgenic mice expressing a B-cell growth and differentiation factor gene (interleukin-5) develop eosinophilia and autoantibody production. J Exp Med 173 2 (1991) 429-437
23. Kopf M., Brombacher F., Hodgkin P.D., et al. IL-5-deficient mice have a developmental defect in CD5+ B-1 cells and lack eosinophilia but have normal antibody and cytotoxic T cell responses. Immunity 4 1 (1996) 15-24
24. Foster P.S., Hogan S.P., Ramsay A.J., et al. Interleukin 5 deficiency abolishes airways eosinophilia, airways hyperreactivity, and lung damage in mouse asthma model. J Exp Med 183 (1996) 195-201
25. Cho J.Y., Miller M., Baek K.J., et al. Inhibition of airway remodeling in IL-5-deficient mice. J Clin Invest 113 4 (2004) 551-560
26. Cantor A.B., and Orkin S.H. Hematopoietic development: a balancing act. Curr Opin Genet Dev 11 5 (2001) 513-519
27. Miyamoto T., and Akashi K. Lineage promiscuous expression of transcription factors in normal hematopoiesis. Int J Hematol 81 5 (2005) 361-367
28. Akashi K. Lineage promiscuity and plasticity in hematopoietic development. Ann N Y Acad Sci 1044 (2005) 125-131
29. McNagny K., and Graf T. Making eosinophils through subtle shifts in transcription factor expression. J Exp Med 195 11 (2002) F43-F47
30. Yamaguchi Y., Nishio H., Kishi K., et al. C/EBPbeta and GATA-1 synergistically regulate activity of the eosinophil granule major basic protein promoter: implication for C/EBPbeta activity in eosinophil gene expression. Blood 94 4 (1999) 1429-1439
31. Querfurth E., Schuster M., Kulessa H., et al. Antagonism between C/EBPbeta and FOG in eosinophil lineage commitment of multipotent hematopoietic progenitors. Genes Dev 14 19 (2000) 2515-2525
32. Hirasawa R., Shimizu R., Takahashi S., et al. Essential and instructive roles of GATA factors in eosinophil development. J Exp Med 195 11 (2002) 1379-1386
33. Yu C., Cantor A.B., Yang H., et al. Targeted deletion of a high-affinity GATA-binding site in the GATA-1 promoter leads to selective loss of the eosinophil lineage in vivo. J Exp Med 195 11 (2002) 1387-1395
34. Du J., Stankiewicz M.J., Liu Y., et al. Novel combinatorial interactions of GATA-1, PU.1, and C/EBPepsilon isoforms regulate transcription of the gene encoding eosinophil granule major basic protein. J Biol Chem 277 45 (2002) 43481-43494
35. Zimmermann N., Colyer J.L., Koch L.E., et al. Analysis of the CCR3 promoter reveals a regulatory region in exon 1 that binds GATA-1. BMC Immunol 6 1 (2005) 7
36. Stopka T., Amanatullah D.F., Papetti M., et al. PU.1 inhibits the erythroid program by binding to GATA-1 on DNA and creating a repressive chromatin structure. EMBO J 24 21 (2005) 3712-3723
37. Du J, Vyas D, Xi Q, et al. Double GAT-1 binding sites Specify PU.1 and GATA-1 synergy in transcriptional regulation of myeloid lineage-specific genes. Nucleic Acids Research 2007; submitted for publication.
38. Zhang D.E., Zhang P., Wang N.D., et al. Absence of granulocyte colony-stimulating factor signaling and neutrophil development in CCAAT enhancer binding protein alpha- deficient mice. Proc Natl Acad Sci U S A 94 2 (1997) 569-574
39. Ackerman S.J., Du J., Xin F., et al. Eosinophilopoiesis: to be or not to be (an eosinophil)? That is the question: transcriptional themes regulating eosinophil genes and development. Respir Med 94 (2000) 1135-1140
40. Du J., Savage M.P., Dekoter R., et al. Impaired eosinophilopoiesis and eosinophil gene expression in PU.1 (Spi-1 oncogene) deficient mice. Exp Hematol (2007) in press
41. Yamanaka R., Barlow C., Lekstrom-Himes J., et al. Impaired granulopoiesis, myelodysplasia, and early lethality in CCAAT/enhancer binding protein epsilon-deficient mice. Proc Natl Acad Sci U S A 94 24 (1997) 13187-13192
42. Yamanaka R., Lekstrom-Himes J., Barlow C., et al. CCAAT/enhancer binding proteins are critical components of the transcriptional regulation of hematopoiesis. [review]. Int J Mol Med 1 1 (1998) 213-221
43. Rosenberg H.F., and Gallin J.I. Neutrophil-specific granule deficiency includes eosinophils. Blood 82 1 (1993) 268-273
44. Klion A.D., Law M.A., Noel P., et al. Safety and efficacy of the monoclonal anti-interleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndrome. Blood 103 8 (2004) 2939-2941
45. Menzies-Gow A., Flood-Page P., Sehmi R., et al. Anti-IL-5 (Mepolizumab) therapy induces bone marrow eosinophil maturational arrest and decreases eosinophil progenitors in the bronchial mucosa of atopic asthmatics. J Allergy Clin Immunol 111 4 (2003) 714-719
46. Clutterbuck E.J., Hirst E.M.A., and Sanderson C.J. Human interleukin-5 (IL-5) regulates the production of eosinophils in human bone marrow cultures: comparison and interaction with IL-1, IL-3, IL-6, and GMCSF. Blood 73 (1989) 1504-1512
47. Seminario M.-C., Saini S.S., MacGlashan Jr. D.W., et al. Intracellular expression and release of FceRIa by human eosinophils. J Immunol 162 (1999) 6893-6900
48. Smith S.J., Ying S., Meng Q., et al. Blood eosinophils from atopic donors express messenger RNA for the alpha, beta, and gamma subunits of the high-affinity IgE receptor (Fc epsilon RI) and intracellular, but not cell surface, alpha subunit protein. J Allergy Clin Immunol 105 2 Pt 1 (2000) 309-317
49. Ackerman S.J., Kephart G.M., Habermann T.M., et al. Localization of eosinophil granule major basic protein in human basophils. J Exp Med 158 (1983) 946-961
50. Ackerman S.J., Weil G.J., and Gleich G.J. Formation of Charcot-Leyden crystals by human basophils. J Exp Med 155 6 (1982) 1597-1609
51. Abu-Ghazaleh R.I., Dunnette S.L., Loegering D.A., et al. Eosinophil granule proteins in peripheral blood granulocytes. J Leukoc Biol 52 6 (1992) 611-618
52. Bochner B.S., and Schleimer R.P. Mast cells, basophils, and eosinophils: distinct but overlapping pathways for recruitment. Immunol Rev 179 (2001) 5-15
53. Voehringer D., van Rooijen N., and Locksley R.M. Eosinophils develop in distinct stages and are recruited to peripheral sites by alternatively activated macrophages. J Leukoc Biol 81 6 (2007) 1434-1444
54. Aizawa H., Zimmermann N., Carrigan P.E., et al. Molecular analysis of human Siglec-8 orthologs relevant to mouse eosinophils: identification of mouse orthologs of Siglec-5 (mSiglec-F) and Siglec-10 (mSiglec-G). Genomics 82 5 (2003) 521-530
55. Zhang J.Q., Biedermann B., Nitschke L., et al. The murine inhibitory receptor mSiglec-E is expressed broadly on cells of the innate immune system whereas mSiglec-F is restricted to eosinophils. Eur J Immunol 34 4 (2004) 1175-1184
56. Kikly K.K., Bochner B.S., Freeman S., et al. Identification of SAF-2, a novel Siglec expressed on eosinophils, mast cells and basophils. J Allergy Clin Immunol 105 (2000) 1093-1100
57. Palframan R.T., Collins P.D., Severs N.J., et al. Mechanisms of acute eosinophil mobilization from the bone marrow stimulated by interleukin 5: the role of specific adhesion molecules and phosphatidylinositol 3-kinase. J Exp Med 188 9 (1998) 1621-1632
58. Palframan R.T., Collins P.D., Williams T.J., et al. Eotaxin induces a rapid release of eosinophils and their progenitors from the bone marrow. Blood 91 7 (1998) 2240-2248
59. Werfel S., Yednock T., Matsumoto K., et al. Functional regulation of b1 integrins and human eosinophils by divalent cations and cytokines. Am J Respir Cell Mol Biol 14 (1996) 45-52
60. Weber C., Kitayama J., and Springer T.A. Differential regulation of b1 and b2 integrin avidity by chemoattractants in eosinophils. Proc Natl Acad Sci USA 93 (1996) 10939-10944
61. Tachimoto H., Burdick M., Hudson S.A., et al. CCR3-active chemokines promote rapid detachment of eosinophils from VCAM-1 in vitro. J Immunol 165 (2000) 2748-2754
62. Minshall E.M., Schleimer R., Cameron L., et al. Interleukin-5 expression in the bone marrow of sensitized Balb/c mice after allergen challenge. Am J Respir Crit Care Med 158 3 (1998) 951-957
63. Groopman J.E., Mitsuyasu R.T., DeLeo M.J., et al. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on myelopoiesis in the acquired immunodeficiency syndrome. N Engl J Med 317 (1987) 593-598
64. Shi H.Z., Xiao C.Q., Zhong D., et al. Effect of inhaled interleukin-5 on airway hyperreactivity and eosinophilia in asthmatics. Am J Respir Crit Care Med 157 1 (1998) 204-209
65. Bochner B.S., Friedman B., Krishnaswami G., et al. Episodic eosinophilia-myalgia-like syndrome in a patient without L-tryptophan use: association with eosinophil activation and increased serum levels of granulocyte-macrophage colony-stimulating factor. J Allergy Clin Immunol 88 4 (1991) 629-636
66. Butterfield J.H., Leiferman K.M., Abrams J., et al. Elevated serum levels of interleukin-5 in patients with the syndrome of episodic angioedema and eosinophilia. Blood 79 3 (1992) 688-692
67. Fang J., Viksman M.Y., Ebisawa M., et al. Increased circulating levels of interleukin-5 in a case of steroid-resistant hypereosinophilic syndrome with ileal involvement. J Allergy Clin Immunol 94 (1994) 129-131
68. Simon H.U., Plotz S.G., Dummer R., et al. Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia. N Engl J Med 341 15 (1999) 1112-1120
69. Mishra A., Hogan S.P., Lee J.J., et al. Fundamental signals that regulate eosinophil homing to the gastrointestinal tract. J Clin Invest 103 12 (1999) 1719-1727
70. Winkel P., Statland B.E., Saunders A.M., et al. Within-day physiologic variation of leukocyte types in healthy subjects as assayed by two automated leukocyte differential analyzers. Am J Clin Pathol 75 5 (1981) 693-700
71. Bochner B.S. Adhesion molecules as therapeutic targets. Immunol Allergy Clin North Am 24 4 (2004) 615-630
72. Gauvreau G.M., Becker A.B., Boulet L.P., et al. The effects of an anti-CD11a mAb, efalizumab, on allergen-induced airway responses and airway inflammation in subjects with atopic asthma. J Allergy Clin Immunol 112 2 (2003) 331-338
73. Shi H.Z., Humbles A., Gerard C., et al. Lymph node trafficking and antigen presentation by endobronchial eosinophils. J Clin Invest 105 7 (2000) 945-953
74. Conus S., Bruno A., and Simon H.U. Leptin is an eosinophil survival factor. J Allergy Clin Immunol 116 6 (2005) 1228-1234
75. Bureau F., Seumois G., Jaspar F., et al. CD40 engagement enhances eosinophil survival through induction of cellular inhibitor of apoptosis protein 2 expression: possible involvement in allergic inflammation. J Allergy Clin Immunol 110 (2002) 443-449
76. Rothenberg M.E., and Hogan S.P. The eosinophil. Annu Rev Immunol 24 (2006) 147-174
77. Simon H.U., Yousefi S., Schranz C., et al. Direct demonstration of delayed eosinophil apoptosis as a mechanism causing tissue eosinophilia. J Immunol 158 8 (1997) 3902-3908
78. Cameron L., Christodoulopoulos P., Lavigne F., et al. Evidence for local eosinophil differentiation within allergic nasal mucosa: inhibition with soluble IL-5 receptor. J Immunol 164 3 (2000) 1538-1545
79. Denburg J.A., and Keith P.K. Systemic aspects of chronic rhinosinusitis. Immunol Allergy Clin North Am 24 1 (2004) 87-102
80. Broide D.H., Lotz M., Cuomo A.J., et al. Cytokines in symptomatic asthma airways. J Allergy Clin Immunol 89 5 (1992) 958-967
81. Kroegel C., Liu M.C., Hubbard W.M., et al. Blood and bronchoalveolar eosinophils in allergic subjects following segmental antigen challenge: surface phenotype, density heterogeneity, and prostanoid production. J Allergy Clin Immunol 93 (1994) 725-734
82. Esnault S., and Malter J.S. GM-CSF regulation in eosinophils. Arch Immunol Ther Exp (Warsz) 50 2 (2002) 121-130
83. Rosenberg H.F., Phipps S., and Foster P.S. Eosinophil trafficking in allergy and asthma. J Allergy Clin Immunol 119 6 (2007) 1303-1310
84. Fryer A.D., Costello R.W., Yost B.L., et al. Antibody to VLA-4, but not to L-selectin, protects neuronal M2 muscarinic receptors in antigen-challenged guinea pig airways. J Clin Invest 99 (1997) 2036-2044
85. Gonzalo J.A., Lloyd C.M., Kremer L., et al. Eosinophil recruitment to the lung in a murine model of allergic inflammation-the role of T cells, chemokines, and adhesion receptors. J Clin Invest 98 10 (1996) 2332-2345
86. Gonzalo J.A., Lloyd C.M., Wen D., et al. The coordinated action of CC chemokines in the lung orchestrates allergic inflammation and airway hyperresponsiveness. J Exp Med 188 1 (1998) 157-167
87. Norris V., Choong L., Tran D., et al. Effect of IVL745, a VLA-4 antagonist, on allergen-induced bronchoconstriction in patients with asthma. J Allergy Clin Immunol 116 4 (2005) 761-767
88. Pero R.S., Borchers M.T., Spicher K., et al. Galphai2-mediated signaling events in the endothelium are involved in controlling leukocyte extravasation. Proc Natl Acad Sci U S A 104 11 (2007) 4371-4376
89. Anwar A.R.F., Moqbel R., Walsh G.M., et al. Adhesion to fibronectin prolongs eosinophil survival. J Exp Med 177 3 (1993) 839-843
90. Georas S.N., McIntyre B.W., Ebisawa M., et al. Expression of a functional laminin receptor (a6b1, VLA-6) on human eosinophils. Blood 82 (1993) 2872-2879
91. Bochner B.S. Cellular adhesion in inflammation. In: Adkinson Jr. N.F., Yunginger J.W., Busse W.W., et al. (Eds). Allergy principles and practice. 6th edition (2003), Mosby, St. Louis (MO) 117-134
92. Broide D.H., Sullivan S., Gifford T., et al. Inhibition of pulmonary eosinophilia in P-selectin- and ICAM-1-deficient mice. Am J Respir Cell Mol Biol 18 2 (1998) 218-225
93. Bochner B.S. Road signs guiding leukocytes along the inflammation superhighway. J Allergy Clin Immunol 106 (2000) 817-828
94. Broide D., and Sriramarao P. Eosinophil trafficking to sites of allergic inflammation. Immunol Rev 179 (2001) 163-172
95. Wardlaw A.J. Molecular basis for selective eosinophil trafficking in asthma: a multistep paradigm. J Allergy Clin Immunol 104 5 (1999) 917-926
96. Bochner B.S., Sterbinsky S.A., Bickel C.A., et al. Differences between human eosinophils and neutrophils in the function and expression of sialic acid-containing counterligands for E-selectin. J Immunol 152 (1994) 774-782
97. Broide D.H., Miller M., Castaneda D., et al. Core 2 oligosaccharides mediate eosinophil and neutrophil peritoneal but not lung recruitment. Am J Physiol Lung Cell Mol Physiol 282 (2002) L259-L266
98. Beeh K.M., Beier J., Meyer M., et al. Bimosiamose, an inhaled small-molecule pan-selectin antagonist, attenuates late asthmatic reactions following allergen challenge in mild asthmatics: a randomized, double-blind, placebo-controlled clinical cross-over-trial. Pulm Pharmacol Ther 19 4 (2006) 233-241
99. Meyer M., Beeh K.M., Beier J., et al. Tolerability and pharmacokinetics of inhaled bimosiamose disodium in healthy males. Br J Clin Pharmacol 63 4 (2007) 451-458
100. Kita H., Adolphson C.R., and Gleich G.J. Biology of eosinophils. In: Adkinson Jr. N.F., Yunginger J.W., Busse W.W., et al. (Eds). Allergy principles and practice. 6th edition (2003), Mosby, Philadelphia 305-332
101. Prin L., Capron M., Tonnel A.B., et al. Heterogeneity of human peripheral blood eosinophils: variability in cell density and cytotoxic ability in relation to the level and the origin of hypereosinophilia. Int Arch Allergy Appl Immunol 72 4 (1983) 336-346
102. Fukuda T., Dunnette S.L., Reed C.E., et al. Increased numbers of hypodense eosinophils in the blood of patients with bronchial asthma. Am Rev Respir Dis 132 5 (1985) 981-985
103. Caulfield J.P., Hein A., Rothenberg M.E., et al. A morphometric study of normodense and hypodense human eosinophils that are derived in vivo and in vitro. Am J Pathol 137 1 (1990) 27-41
104. Matsumoto K., Appiah-Pippim J., Schleimer R.P., et al. CD44 and CD69 represent different types of cell surface activation markers for human eosinophils. Am J Respir Cell Mol Biol 18 (1998) 860-866
105. Koenderman L., van der Bruggen T., Schweizer R.C., et al. Eosinophil priming by cytokines: from cellular signal to in vivo modulation. Eur Respir J Suppl 22 (1996) 119s-125s
106. Brandt E.B., Zimmermann N., Muntel E.E., et al. The alpha4bbeta7-integrin is dynamically expressed on murine eosinophils and involved in eosinophil trafficking to the intestine. Clin Exp Allergy 36 4 (2006) 543-553
107. Blanchard C., Wang N., Stringer K.F., et al. Eotaxin-3 and a uniquely conserved gene-expression profile in eosinophilic esophagitis. J Clin Invest 116 2 (2006) 536-547
108. Katoh S., Matsumoto N., Kawakita K., et al. A role for CD44 in an antigen-induced murine model of pulmonary eosinophilia. J Clin Invest 111 10 (2003) 1563-1570
109. Zimmermann N., Hershey G.K., Foster P.S., et al. Chemokines in asthma: cooperative interaction between chemokines and IL-13. J Allergy Clin Immunol 111 2 (2003) 227-242
110. Menzies-Gow A., Ying S., Sabroe I., et al. Eotaxin (CCL11) and eotaxin-2 (CCL24) induce recruitment of eosinophils, basophils, neutrophils, and macrophages as well as features of early- and late-phase allergic reactions following cutaneous injection in human atopic and nonatopic volunteers. J Immunol 169 5 (2002) 2712-2718
111. Beck L.A., Dalke S., Leiferman K.M., et al. Cutaneous injection of RANTES causes eosinophil recruitment: comparison of nonallergic and allergic human subjects. J Immunol 159 6 (1997) 2962-2972
112. Pereira S., Clark T., Darby Y., et al. Effects of anti-eotaxin monoclonal antibody CAT-213 on allergen-induced rhinitis. [abstract]. J Allergy Clin Immunol 111 (2003) S268
113. Main S., Handy R., Wilton J., et al. A potent human anti-eotaxin1 antibody, CAT-213: isolation by phage display and in vitro and in vivo efficacy. J Pharmacol Exp Ther 319 3 (2006) 1395-1404
114. Moqbel R., and Lacy P. Exocytotic events in eosinophils and mast cells. Clin Exp Allergy 29 8 (1999) 1017-1022
115. Tager A.M., Dufour J.H., Goodarzi K., et al. BLTR mediates leukotriene B(4)-induced chemotaxis and adhesion and plays a dominant role in eosinophil accumulation in a murine model of peritonitis. J Exp Med 192 3 (2000) 439-446
116. Nagata K., Hirai H., Tanaka K., et al. CRTH2, an orphan receptor of T-helper-2-cells, is expressed on basophils and eosinophils and responds to mast cell-derived factor(s). FEBS Lett 459 2 (1999) 195-199
117. Hirai H., Tanaka K., Yoshie O., et al. Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2. J Exp Med 193 2 (2001) 255-261
118. O'Reilly M., Alpert R., Jenkinson S., et al. Identification of a histamine H4 receptor on human eosinophils-role in eosinophil chemotaxis. J Recept Signal Transduct Res 22 1-4 (2002) 431-448
119. Sihra B.S., Kon O.M., Grant J.A., et al. Expression of high-affinity IgE receptors (FceRI) on peripheral blood basophils, monocytes, and eosinophils in atopic and nonatopic subjects: relationship to total serum IgE concentrations. J Allergy Clin Immunol 99 5 (1997) 699-706
120. Kita H., Kaneko M., Bartemes K.R., et al. Does IgE bind to and activate eosinophils from patients with allergy?. J Immunol 162 (1999) 6901-6911
121. Kayaba H., Dombrowicz D., Woerly G., et al. Human eosinophils and human high affinity IgE receptor transgenic mouse eosinophils express low levels of high affinity IgE receptor, but release IL-10 upon receptor activation. J Immunol 167 2 (2001) 995-1003
122. Bandeira-Melo C., and Weller P.F. Eosinophils and cysteinyl leukotrienes. Prostaglandins Leukot Essent Fatty Acids 69 2-3 (2003) 135-143
123. Gharaee-Kermani M., and Phan S.H. The role of eosinophils in pulmonary fibrosis. [review]. Int J Mol Med 1 1 (1998) 43-53
124. Levi-Schaffer F., Garbuzenko E., Rubin A., et al. Human eosinophils regulate human lung- and skin-derived fibroblast properties in vitro: a role for transforming growth factor beta (TGF-beta). Proc Natl Acad Sci U S A 96 17 (1999) 9660-9665
125. Spry C.J. The pathogenesis of endomyocardial fibrosis: the role of the eosinophil. Springer Semin Immunopathol 11 4 (1989) 471-477
126. Dvorak A.M., Ackerman S.J., Furitsu T., et al. Mature eosinophils stimulated to develop in human-cord blood mononuclear cell cultures supplemented with recombinant human interleukin-5. II. Vesicular transport of specific granule matrix peroxidase, a mechanism for effecting piecemeal degranulation. Am J Pathol 140 4 (1992) 795-807
127. Melo R.C., Perez S.A., Spencer L.A., et al. Intragranular vesiculotubular compartments are involved in piecemeal degranulation by activated human eosinophils. Traffic 6 10 (2005) 866-879
128. Logan M.R., Odemuyiwa S.O., and Moqbel R. Understanding exocytosis in immune and inflammatory cells: the molecular basis of mediator secretion. J Allergy Clin Immunol 111 5 (2003) 923-932
129. Moqbel R., and Coughlin J.J. Differential secretion of cytokines. Sci STKE 338 (2006) 26
130. Dvorak A.M., Ackerman S.J., and Weller P.F. Subcellular morphology and biochemistry of eosinophils. In: Harris J.R. (Ed). Blood cell biochemistry: megakaryocytes, platelets, macrophages and eosinophils vol. 2 (1990), Plenum Publishing Corporation, London 237-344
131. Gleich G.J. Mechanisms of eosinophil-associated inflammation. J Allergy Clin Immunol 105 4 (2000) 651-663
132. Martin L.B., Kita H., Leiferman K.M., et al. Eosinophils in allergy: role in disease, degranulation, and cytokines. Int Arch Allergy Immunol 109 3 (1996) 207-215
133. Thomas L.L., and Page S.M. Inflammatory cell activation by eosinophil granule proteins. Chem Immunol 76 (2000) 99-117
134. Jacoby D.B., Costello R.M., and Fryer A.D. Eosinophil recruitment to the airway nerves. J Allergy Clin Immunol 107 2 (2001) 211-218
135. Rochester C.L., Ackerman S.J., Zheng T., et al. Eosinophil-fibroblast interactions. Granule major basic protein interacts with IL-1 and transforming growth factor-beta in the stimulation of lung fibroblast IL-6-type cytokine production. J Immunol 156 11 (1996) 4449-4456
136. Sedgwick J.B., Calhoun W.J., Vrtis R.F., et al. Comparison of airway and blood eosinophil function after in vivo antigen challenge. J Immunol 149 11 (1992) 3710-3718
137. Gleich G.J., Hunt L.W., Bochner B.S., et al. Glucocorticoid effects on human eosinophils. In: Schleimer R.P., Busse W.W., and O'Byrne P. (Eds). Inhaled glucocorticoids in asthma: mechanisms and clinical actions (1996), Marcel Dekker, Inc., New York 279-308
138. Stellato C., Matsukura S., Fal A., et al. Differential regulation of epithelial-derived C-C chemokine expression by IL-4 and the glucocorticoid budesonide. J Immunol 163 10 (1999) 5624-5632
139. Druilhe A., Letuve S., and Pretolani M. Glucocorticoid-induced apoptosis in human eosinophils: mechanisms of action. Apoptosis 8 5 (2003) 481-495
140. Fan J., Heller N.M., Gorospe M., et al. The role of post-transcriptional regulation in chemokine gene expression in inflammation and allergy. Eur Respir J 26 5 (2005) 933-947
141. Simon H.U. Molecules involved in the regulation of eosinophil apoptosis. Chem Immunol Allergy 91 (2006) 49-58
142. Okada S., Hagan J.B., Kato M., et al. Lidocaine and its analogues inhibit IL-5-mediated survival and activation of human eosinophils. J Immunol 160 8 (1998) 4010-4017
143. Alam R., Forsythe P., Stafford S., et al. Transforming growth factor beta abrogates the effects of hematopoietins on eosinophils and induces their apoptosis. J Exp Med 179 3 (1994) 1041-1045
144. Nutku E., Aizawa H., Hudson S.A., et al. Ligation of Siglec-8: a selective mechanism for induction of human eosinophil apoptosis. Blood 101 12 (2003) 5014-5020
145. Zhang M., Angata T., Cho J.Y., et al. Defining the in vivo function of Siglec-F, a CD33-related Siglec expressed on mouse eosinophils. Blood 109 (2007) 4280-4287
146. Matsumoto K., Schleimer R.P., Saito H., et al. Induction of apoptosis in human eosinophils by anti-fas antibody treatment in vitro. Blood 86 (1995) 1437-1443
147. Matsumoto K., Terakawa M., Miura K., et al. Extremely rapid and intense induction of apoptosis in human eosinophils by anti-CD30 antibody treatment in vitro. J Immunol 172 4 (2004) 2186-2193
148. von Gunten S., Vogel M., Schaub A., et al. Intravenous immunoglobulin preparations contain anti-Siglec-8 autoantibodies. J Allergy Clin Immunol 119 4 (2007) 1005-1011
149. Klion A.D., Bochner B.S., Gleich G.J., et al. Approaches to the treatment of hypereosinophilic syndromes: a workshop summary report. J Allergy Clin Immunol 117 6 (2006) 1292-1302
150. Cools J., DeAngelo D.J., Gotlib J., et al. A tyrosine kinase created by fusion of the PDGFRα and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 348 13 (2003) 1201-1214
151. Munitz A., Bachelet I., and Levi-Schaffer F. Reversal of airway inflammation and remodeling in asthma by a bispecific antibody fragment linking CCR3 to CD300a. J Allergy Clin Immunol 118 5 (2006) 1082-1089
152. Ackerman S.J., and Butterfield J.H. Eosinophilia, eosinophil-associated diseases and the hypereosinophilic syndromes. In: Hoffman R.H., Benz E.J., Shattil S.J., et al. (Eds). Hematology, basic principles and practice. 4th edition (2004), Churchill Livingstone/W.B. Saunders, Philadelphia 763-786
153. Klion A.D., Rothenberg M.E., Murray J.J., et al. Safety and tolerability of anti-IL-5 monoclonal antibody (Mepolizumab) therapy in patients with HES: a multicenter, randomized, double-blind, placebo-controlled trial. Blood [ASH Annual Meeting Abstracts] 108 (2006) 2694
154. Yamada Y., Rothenberg M.E., Lee A.W., et al. The FIP1L1-PDGFRA fusion gene cooperates with IL-5 to induce murine hypereosinophilic syndrome (HES)/chronic eosinophilic leukemia (CEL)-like disease. Blood 107 10 (2006) 4071-4079